<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Xenobiot</journal-id><journal-id journal-id-type="iso-abbrev">J Xenobiot</journal-id><journal-id journal-id-type="publisher-id">jox</journal-id><journal-title-group><journal-title>Journal of Xenobiotics</journal-title></journal-title-group><issn pub-type="ppub">2039-4705</issn><issn pub-type="epub">2039-4713</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407530</article-id><article-id pub-id-type="pmc">PMC12101174</article-id>
<article-id pub-id-type="doi">10.3390/jox15030066</article-id><article-id pub-id-type="publisher-id">jox-15-00066</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">COMT</italic> Genetic Variants and BDNF Level Associations with Cannabinoid Plasma Exposure: A Preliminary Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8540-6709</contrib-id><name><surname>Manca</surname><given-names>Alessandra</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref><xref rid="fn1-jox-15-00066" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Valz</surname><given-names>Cristina</given-names></name><xref rid="af2-jox-15-00066" ref-type="aff">2</xref><xref rid="fn1-jox-15-00066" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2585-9607</contrib-id><name><surname>Chiara</surname><given-names>Francesco</given-names></name><xref rid="af3-jox-15-00066" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0860-280X</contrib-id><name><surname>Palermiti</surname><given-names>Alice</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9264-0114</contrib-id><name><surname>Mula</surname><given-names>Jacopo</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2303-6463</contrib-id><name><surname>Soloperto</surname><given-names>Sara</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5344-9659</contrib-id><name><surname>Antonucci</surname><given-names>Miriam</given-names></name><xref rid="af4-jox-15-00066" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5973-9948</contrib-id><name><surname>De Nicol&#x000f2;</surname><given-names>Amedeo</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Luxardo</surname><given-names>Nicola</given-names></name><xref rid="af2-jox-15-00066" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Imperiale</surname><given-names>Daniele</given-names></name><xref rid="af5-jox-15-00066" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Vischia</surname><given-names>Flavio</given-names></name><xref rid="af6-jox-15-00066" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>De Cori</surname><given-names>David</given-names></name><xref rid="af6-jox-15-00066" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1977-9694</contrib-id><name><surname>Cusato</surname><given-names>Jessica</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref><xref rid="c1-jox-15-00066" ref-type="corresp">*</xref><xref rid="fn2-jox-15-00066" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1321-4126</contrib-id><name><surname>D&#x02019;Avolio</surname><given-names>Antonio</given-names></name><xref rid="af1-jox-15-00066" ref-type="aff">1</xref><xref rid="fn2-jox-15-00066" ref-type="author-notes">&#x02021;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ariyoshi</surname><given-names>Noritaka</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jox-15-00066"><label>1</label>Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, 10149 Turin, Italy</aff><aff id="af2-jox-15-00066"><label>2</label>SC Terapia del Dolore, ASL Citt&#x000e0; di Torino, 10144 Turin, Italy<email>nicola.luxardo@aslcittaditorino.it</email> (N.L.)</aff><aff id="af3-jox-15-00066"><label>3</label>Laboratory of Clinical Pharmacology San Luigi A.O.U., Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy</aff><aff id="af4-jox-15-00066"><label>4</label>SCDU Infectious Diseases, Amedeo di Savoia Hospital, ASL Citt&#x000e0; di Torino, 10149 Turin, Italy</aff><aff id="af5-jox-15-00066"><label>5</label>Neurology Unit, Maria Vittoria Hospital, ASL Citt&#x000e0; di Torino, 10144 Turin, Italy</aff><aff id="af6-jox-15-00066"><label>6</label>Psychiatric Unit West, Department of Mental Health, 10149 Turin, Italy</aff><author-notes><corresp id="c1-jox-15-00066"><label>*</label>Correspondence: <email>jessica.cusato@unito.it</email>; Tel.: +39-011-4393841; Fax: +39-011-4393996</corresp><fn id="fn1-jox-15-00066"><label>&#x02020;</label><p>These authors equally contributed to this work and share first authorship.</p></fn><fn id="fn2-jox-15-00066"><label>&#x02021;</label><p>These authors equally contributed to this work and share last authorship.</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>15</volume><issue>3</issue><elocation-id>66</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic toggle="yes">Cannabis sativa</italic> L. shows potent anti-inflammatory activity, resulting in an interesting pharmacological option for pain management. The aim of the study was to evaluate the association between pharmacogenetics, neurological and inflammatory biomarkers, and cannabinoid plasma exposure in patients treated with cannabis. A total of 58 patients with a diagnosis of neuropathic and chronic pain treated with medical cannabis were analyzed. Cannabis was administered as a decoction (n = 47) and as inhaled cannabis (n = 11): 30 patients were treated with cannabis with high THC, while 28 patients were treated with cannabis with reduced THC (plus CBD). Cannabinoid plasma concentrations were obtained with UHPLC-MS/MS. Allelic discrimination was assessed by real-time PCR. Inflammation biomarkers (e.g., interleukin-10) were analyzed by ELISA, neurofilaments light chain (NFL), and brain-derived neurotrophic factor (BDNF) by Single Molecule Array. A statistically significant difference in IL-10 (<italic toggle="yes">p</italic> = 0.009) and BDNF (<italic toggle="yes">p</italic> = 0.004) levels was observed comparing patients treated with decoction and inhaled cannabis. BDNF and NFL results correlated with cannabinoid concentrations. Concerning genetics, the <italic toggle="yes">COMT</italic> 680 T&#x0003e;C genetic variant influences cannabinoid plasma levels, including &#x00394;9-THC (<italic toggle="yes">p</italic> = 0.017). Conclusions: This study shows a possible impact of some genetic variants on cannabinoid plasma exposure, other than a possible role of medical cannabis on inflammation-related and neuronal impairment factor levels. Further studies in larger cohorts are required.</p></abstract><kwd-group><kwd>THC</kwd><kwd>genetics</kwd><kwd>cannabinoids</kwd><kwd>pain</kwd><kwd>BDNF</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-jox-15-00066"><title>1. Introduction</title><p><italic toggle="yes">Cannabis sativa</italic> L. use has been reported in about 147 million people worldwide [<xref rid="B1-jox-15-00066" ref-type="bibr">1</xref>]. It is one of the most ancient cultivated plants due to its adaptability to a wide range of habitats and its multiple uses, including food, fiber, and a drug plant [<xref rid="B2-jox-15-00066" ref-type="bibr">2</xref>].</p><p>The first evidence of its utilization in humans dates back to about 10,000 years ago: cannabis fruit and seed fossils have been found in the Okinoshima archeological site of the Mesolithic Age (Boso Peninsula, central Japan) [<xref rid="B3-jox-15-00066" ref-type="bibr">3</xref>].</p><p>In Italy, the authorization, cultivation, import, export, and distribution of cannabis are regulated by the Ministerial Decree of 9 November 2015 [<xref rid="B4-jox-15-00066" ref-type="bibr">4</xref>].</p><p>The main therapeutic indication for the use of medical cannabis (MC) is analgesia in pathologies with spasticity associated with pain (such as in multiple sclerosis) and in chronic pain, in particular in neurogenic pain.</p><p>MC contains a large variety of chemical compounds, including the psychoactive cannabinoid delta-9-tetrahydrocannabinol (&#x02206;9-THC) and the non-psychoactive cannabidiol (CBD). These cannabinoids interact with the endocannabinoid system which plays an important role in several physiological processes such as nervous functions, neurogenesis, neuroprotection, depression, memory, cognition, and painful sensation [<xref rid="B5-jox-15-00066" ref-type="bibr">5</xref>,<xref rid="B6-jox-15-00066" ref-type="bibr">6</xref>,<xref rid="B7-jox-15-00066" ref-type="bibr">7</xref>].</p><p>The endocannabinoid system resulted in an interesting pharmacological target for many diseases, including pain and neurodegenerative conditions [<xref rid="B8-jox-15-00066" ref-type="bibr">8</xref>,<xref rid="B9-jox-15-00066" ref-type="bibr">9</xref>,<xref rid="B10-jox-15-00066" ref-type="bibr">10</xref>].</p><p>Cannabinoid-receptor type 1 (CB1) is present in the central nervous system (in the neocortex, cerebellum, and limbic system) and in the peripheral nervous system. Cannabinoid-receptor type 2 (CB2) has been identified in lymphocytes, macrophages, and mast cells in the immune system and in microglia cells and astrocytes in the central nervous system [<xref rid="B11-jox-15-00066" ref-type="bibr">11</xref>]. CB1 activation mediates drug and natural rewards, such as sexual activity, social interaction, and food consumption [<xref rid="B12-jox-15-00066" ref-type="bibr">12</xref>]. CB2 receptor agonists exhibit antinociceptive activity in models of inflammatory and nociceptive pain, modulating the immune responses and reducing the release of pro-inflammatory cytokines [<xref rid="B13-jox-15-00066" ref-type="bibr">13</xref>]. These effects may be further enhanced through interactions with other systems, such as activation of the peroxisome proliferator-activated receptor &#x003b1; (PPAR-&#x003b1;), and modulation of transient receptor potential vanilloid type 1 (TRPV1) and &#x003b1;2-adrenoceptor pathways [<xref rid="B14-jox-15-00066" ref-type="bibr">14</xref>,<xref rid="B15-jox-15-00066" ref-type="bibr">15</xref>,<xref rid="B16-jox-15-00066" ref-type="bibr">16</xref>].</p><p>Furthermore, cannabinoids show activity against different types of pain: thermal and noxious, cancer, postoperative and that related to spinal cord and traumatic nerve injury and toxic insults [<xref rid="B17-jox-15-00066" ref-type="bibr">17</xref>,<xref rid="B18-jox-15-00066" ref-type="bibr">18</xref>]. These molecules have also potent anti-inflammatory activity: over-inflammation is present in many pathologies, such as cancer, asthma, rheumatoid arthritis, multiple sclerosis, hepatitis, colitis, and dermatologic diseases [<xref rid="B7-jox-15-00066" ref-type="bibr">7</xref>]. &#x02206;9-THC and CBD showed anti-inflammatory and immune-suppressive properties interacting with CB1 and CB2 receptors [<xref rid="B19-jox-15-00066" ref-type="bibr">19</xref>]. In this context, in a study in a murine model [<xref rid="B20-jox-15-00066" ref-type="bibr">20</xref>], the GPR55 receptor modulates proinflammatory cytokines (such as interleukin (IL)-4, IL-10, interferon gamma), reducing hyperalgesia.</p><p>Cannabinoids are able to downregulate the production of cytokines and chemokines, suppressing inflammatory responses [<xref rid="B19-jox-15-00066" ref-type="bibr">19</xref>]: as an example, CBD could modulate inflammation influencing the release of some pro-inflammatory cytokines, such as tumor necrosis factor &#x003b1; (TNF-&#x003b1;) [<xref rid="B21-jox-15-00066" ref-type="bibr">21</xref>]. No data on possible associations between cannabinoid plasma exposure and inflammation-related biomarkers are present in the literature.</p><p>Furthermore, the role of CBD in reducing depression by increasing brain-derived neurotropic factor (BDNF) has also been suggested [<xref rid="B22-jox-15-00066" ref-type="bibr">22</xref>]. BDNF is a neurotrophin involved in the survival, activity, and growth of neurons [<xref rid="B23-jox-15-00066" ref-type="bibr">23</xref>]. It has been recognized as an important pain modulator, regulating central and peripheral synaptic plasticity. It is also involved in neuropathic and inflammatory pain due to its role in sensory neurotransmission in spinal and supraspinal level nociceptive pathways. In a study, elderly individuals with higher peripheral BDNF levels showed reduced chances of developing Alzheimer&#x02019;s disease [<xref rid="B24-jox-15-00066" ref-type="bibr">24</xref>]. BDNF exposure resulted in changes in other neurodegenerative and mental health disorders [<xref rid="B25-jox-15-00066" ref-type="bibr">25</xref>]. Reduced BDNF levels may indicate a lack of trophic support, potentially contributing to neuronal degeneration [<xref rid="B26-jox-15-00066" ref-type="bibr">26</xref>]. For these reasons, BDNF has been proposed as a biomarker of neuroprotection [<xref rid="B27-jox-15-00066" ref-type="bibr">27</xref>,<xref rid="B28-jox-15-00066" ref-type="bibr">28</xref>].</p><p>In the context of tailored medicine, pharmacogenomics is a crucial tool for personalizing pain treatment with MC [<xref rid="B29-jox-15-00066" ref-type="bibr">29</xref>]. According to the literature, several genes encoding enzymes (such as cytochromes P450, CYP) are involved in the cannabinoid biotransformation [<xref rid="B29-jox-15-00066" ref-type="bibr">29</xref>,<xref rid="B30-jox-15-00066" ref-type="bibr">30</xref>], impacting the absorption, distribution, metabolism and elimination of these molecules, consequently affecting efficacy and adverse effect risk. THC is first metabolized in the liver by CYPs into 11-Hydroxy-&#x00394;9-tetrahydrocannabinol (11-hydroxy-THC) and then oxidized into 11-Nor-9-carboxy-&#x00394;9-tetrahydrocannabinol (THC-COOH), which may be glucuronidated to 11-nor-9-carboxy-THC glucuronide. The main hepatic enzymes involved in THC metabolism are CYP2C19, CYP2C9, and CYP3A4. Also, extra-hepatic tissues express CYPs, such as the brain and small intestine, and have a role in cannabinoid metabolism [<xref rid="B31-jox-15-00066" ref-type="bibr">31</xref>]. CBD is a substrate of CYP2C19, CYP1A1, CYP3A4, CYP1A2, CYP2C9, and CYP2D6, and it is mainly hydroxylated into 7-hydroxy cannabidiol (7-OH-CBD) [<xref rid="B32-jox-15-00066" ref-type="bibr">32</xref>].</p><p>In addition, the <italic toggle="yes">ABCB1</italic> gene encodes the P-glycoprotein, which is an efflux pump potentially affecting the distribution and bioavailability of MC metabolites [<xref rid="B30-jox-15-00066" ref-type="bibr">30</xref>,<xref rid="B33-jox-15-00066" ref-type="bibr">33</xref>].</p><p>Few data are available in this context; thus, the aim of the present preliminary study was to investigate inflammation-related and neurological marker levels in individuals treated with MC.</p><p>In addition, the impact of pharmacogenetics was evaluated: variants of genes encoding cytochromes and transporters involved in cannabinoid metabolism and transport were investigated.</p></sec><sec id="sec2-jox-15-00066"><title>2. Materials and Methods</title><sec sec-type="subjects" id="sec2dot1-jox-15-00066"><title>2.1. Characteristics of Enrolled Patients</title><p>Patients with neuropathic and chronic pain treated with MC were enrolled at the &#x0201c;SC Terapia del Dolore&#x02014;ASL Citt&#x000e0; di Torino&#x0201d; at the &#x0201c;Oftalmico&#x0201d; hospital (Turin, Italy). Nine patients were excluded from the statistical analysis due to incorrect MC decoction intake (e.g., skipped doses).</p><p>The study was performed in compliance with the Declaration of Helsinki and local review board regulations; all patients gave written informed consent, according to the local ethics committee standards (&#x0201c;Cannabis terapeutica nei pazienti affetti da dolore neuropatico: studio osservazionale&#x0201d;, approved by Ethical Committee &#x0201c;A.O.U. CITTA&#x02019; DELLA SALUTE E DELLA SCIENZA DI TORINO&#x02014;A.O. ORDINE MAURIZIANO DI TORINO&#x02014;A.S.L. CITT&#x000c0; DI TORINO&#x0201d;, n&#x000b0; 0131170 del 25 November 2022).</p><p>Inclusion criteria were MC treatment for at least 15 days; exclusion criteria included age under 18 years.</p><p>In this study, 47 individuals were treated with oral MC (decoction), while 11 patients were treated with inhaled MC.</p><p>For MC decoction preparation, the following procedure was used: 100 mL of cold water for every 100 mg of cannabis was used. It was recommended to use 100 mL of water. Heat to boiling and then let it simmer, covered, for 15 min (not exceeding 30 min total boiling time). The decoction should cool for about 15 min before filtering and then freshly consumed.</p><p>Inhalation as a route of administration was chosen by patients, in agreement with the clinician. Indeed, if oral administration (decoction) did not produce the expected pharmacological effect, or when the physician accounted it appropriate, inhalation was used as an alternative method of administration with the use of a personal vaporizer with filtered hot air.</p><p>The correct dose for each patient was determined by the clinician, based on the type of disease and pain severity: MC has been used to induce analgesia in patients resistant to conventional treatments (e.g., opioids). All the patients were na&#x000ef;ve for MC administration.</p><p>Dried cannabis flowers for decoction preparation or for vaporization were provided by the hospital pharmacy at the institution, as a clinical routine. The frequency of the administration was once daily.</p><p>Patients were treated with cannabis with high THC, while 28 patients with low-THC cannabis formulations containing CBD.</p><p>Following dried flower tops of different varieties of <italic toggle="yes">Cannabis</italic> were used:<list list-type="bullet"><list-item><p>Bedrocan<sup>&#x000ae;</sup> (THC level standardized at 19% and with a CBD level &#x0003c; 1%);</p></list-item><list-item><p>Bediol<sup>&#x000ae;</sup> (THC and CBD levels standardized at concentrations of 6.5% and 8%, respectively);</p></list-item><list-item><p>FM2<sup>&#x000ae;</sup> (THC and CBD levels standardized at concentrations of 5&#x02013;8% and 7.5&#x02013;12%, respectively);</p></list-item><list-item><p>Pedanios<sup>&#x000ae;</sup> 22/1 (THC and CBD levels standardized at concentrations of 22% and &#x0003c;1%, respectively).</p></list-item></list></p><p>Bediol<sup>&#x000ae;</sup> and Bedrocan<sup>&#x000ae;</sup> (Bedrocan International BV, Veendam, The Netherlands) were the main varieties used; when they were not available, FM2<sup>&#x000ae;</sup> (Military Chemical and Pharmaceutical Institution of Florence, Florence, Italy) and Pedanios<sup>&#x000ae;</sup> (AURORA <italic toggle="yes">Cannabis</italic> Enterprises Inc., Edmonton, AB, Canada) were administered.</p></sec><sec id="sec2dot2-jox-15-00066"><title>2.2. Pharmacokinetic Analyses</title><p>Cannabinoid metabolites were quantified in plasma after reaching the steady state (at least 15 days after starting therapy): plasma was obtained from blood withdrawals in EDTA tubes immediately before the dose administration of the day (C<sub>trough</sub>). Whole blood was centrifuged at 1400&#x000d7; <italic toggle="yes">g</italic> for 10 min at 4 &#x000b0;C, in order to obtain plasma samples which were stored at &#x02212;80 &#x000b0;C until the analysis. Cannabinoid plasma levels were evaluated using a previously published fully validated method [<xref rid="B34-jox-15-00066" ref-type="bibr">34</xref>]. The whole chromatographic run was completed in 10.0 min and an optimal chromatographic separation between all analytes was obtained. Considered analytes were as follows: &#x00394;9-THC (&#x00394;9-tetrahydrocannabinol), 11-OH-THC (11-Hydroxy-&#x00394;9-tetrahydrocannabinol), COOH-THC, COOH-THC-glucuronide, CBD, 7-OH-CBD, tetrahydrocannabinolic acid (THCA), and cannabidiolic acid (CBDA).</p></sec><sec id="sec2dot3-jox-15-00066"><title>2.3. Genetic Polymorphism Analyses</title><p>Whole blood was collected in EDTA tubes: DNA was extracted using the QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). These kits contain columns allowing DNA purification starting from 200 &#x000b5;L of whole blood.</p><p>Allelic discrimination was performed using RT-PCR (BIORAD, Milan, Italy).</p><p>The following allelic variants were analyzed: <italic toggle="yes">ABCB1</italic> 3435 C&#x0003e;T (rs1045642), <italic toggle="yes">ABCB1</italic> 2677 G&#x0003e;A (rs2032582), <italic toggle="yes">ABCB1</italic> 1236 C&#x0003e;T (rs1128503), <italic toggle="yes">ABCG2 421</italic> C&#x0003e;A (rs2231142), <italic toggle="yes">ABCG2</italic> 1194+928 T&#x0003e;C (rs13120400), <italic toggle="yes">CYP2D6</italic> 4180 C&#x0003e;G (rs1135840), <italic toggle="yes">CYP1A1</italic> 7294 C&#x0003e;A (rs2606345), <italic toggle="yes">CYP1A2</italic> 890 C&#x0003e;T (rs2470890), <italic toggle="yes">CYP2C19*2</italic> G&#x0003e;A (rs4244285), <italic toggle="yes">CYP1A2</italic> 32035 A&#x0003e;C (rs762551), <italic toggle="yes">BSEP</italic> T&#x0003e;C (rs2287622), <italic toggle="yes">CYP3A4*1B</italic> G&#x0003e;A (rs2740574), <italic toggle="yes">CYP2C9*3</italic> 1075 A&#x0003e;C, <italic toggle="yes">CYP2C9*2</italic> 430 C&#x0003e;T, <italic toggle="yes">COMT</italic> 680 T&#x0003e;C (rs4680), <italic toggle="yes">GHC1</italic> 841 T&#x0003e;C (rs841), <italic toggle="yes">OPRM1</italic> 971 T&#x0003e;C (rs1799971), <italic toggle="yes">TRPV1</italic> 080 G&#x0003e;A (rs8065080).</p><p>These SNPs were selected because the corresponding genes encode for enzymes, transporters, and receptors involved in the metabolism, transport, and activity of cannabinoids. They were selected based on their allelic frequency, which is commonly represented in the Caucasian population.</p></sec><sec id="sec2dot4-jox-15-00066"><title>2.4. ELISA Tests</title><p>In this study, the BT LAB kit direct method (Bioassay Technology Laboratory, Birmingham, UK) was used to quantify inflammation-related biomarkers in plasma. IL-6, IL-10, and TNF-&#x003b1; plasma levels were analyzed.</p></sec><sec id="sec2dot5-jox-15-00066"><title>2.5. SiMoA<sup>&#x000ae;</sup> Tests</title><p>Plasma specimens were analyzed using Single Molecule Array (SiMoA<sup>&#x000ae;</sup> SR-X, Quanterix<sup>&#x000ae;</sup> Billerica, MA, USA) for markers of neuronal damage, signaling, and plasticity: NFL and BDNF were assessed.</p></sec><sec id="sec2dot6-jox-15-00066"><title>2.6. Statistical Analyses</title><p>The Shapiro&#x02013;Wilk test was used to assess the normality of all continuous variables. The correspondence of each factor, normal or non-normal, was further evaluated using the Kolmogorov&#x02013;Smirnov test. Non-normally distributed variables were described using median and interquartile range (IQR), while categorical variables were reported as counts and percentages. Kruskal&#x02013;Wallis and Mann&#x02013;Whitney tests were used to identify differences in continuous variables, with two-sided <italic toggle="yes">p</italic>-values &#x0003c; 0.05 considered statistically significant. Finally, the predictive power of the variables under investigation was assessed using univariate (<italic toggle="yes">p</italic> &#x0003c; 0.05) and multivariate (<italic toggle="yes">p</italic> &#x0003c; 0.05) linear regression analysis.</p><p>All statistical analyses were performed using IBM SPSS Statistics software, version 28.0 for Windows (Chicago, IL, USA).</p></sec></sec><sec sec-type="results" id="sec3-jox-15-00066"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-jox-15-00066"><title>3.1. Characteristics of Enrolled Patients</title><p>In this study, 67 patients were enrolled at the &#x0201c;SC Terapia del Dolore&#x02014;ASL Citt&#x000e0; di Torino&#x0201d; at the &#x0201c;Oftalmico&#x0201d; hospital (Turin, Italy); 9 patients were excluded from the statistical analysis due to incorrect MC decoction intake (e.g., missing doses).</p><p>Patients were affected by neuropathic and chronic pain caused by various conditions: 46.6% of patients had fibromyalgia, 8.6% had headaches, 6.9% were oncologic patients, and 65.5% were polytraumatized individuals.</p><p>Patient characteristics are reported in <xref rid="jox-15-00066-t001" ref-type="table">Table 1</xref>: 47 patients were treated with MC decoction, and 11 were treated with inhaled MC; no patient received both routes of administration. Additionally, 51.7% (n = 30) of patients were treated with MC with high THC content, while 48.3% (n = 28) received MC with lower THC and standardized CBD concentrations (6.5% and 8%, respectively).</p><p>The most common dose range was 0&#x02013;250 mg of cannabis per day for patients treated with both oral and inhaled MC. All dosages are reported in <xref rid="jox-15-00066-t002" ref-type="table">Table 2</xref>.</p><p>Cannabinoid plasma levels (ng/mL) are reported in <xref rid="jox-15-00066-t003" ref-type="table">Table 3</xref> and <xref rid="jox-15-00066-t004" ref-type="table">Table 4</xref>.</p><p>Most patients were on polypharmacy, considering their various diagnoses: 20 patients were treated with antidepressants (39.2%), 16 with anti-inflammatory drugs (31.4%), 21 with opioids (41.2%), 16 with anticonvulsants (31.4%), 15 with cardiovascular drugs (29.4%), 9 with vitamin D supplementation (17.6%), 17 with anti-anxiety medications (33.3%), and 26 with other drugs (89.7%), as reported in <xref rid="app1-jox-15-00066" ref-type="app">Supplementary Table S1</xref>.</p></sec><sec id="sec3dot2-jox-15-00066"><title>3.2. Biomarker Concentrations</title><p>TNF-&#x003b1;, IL-6, IL-10, BDNF, and NFL concentrations were quantified in plasma, and their median concentrations are reported in <xref rid="jox-15-00066-t005" ref-type="table">Table 5</xref>.</p><p>A statistically significant difference in IL-10 (<italic toggle="yes">p</italic> = 0.009) and BDNF (<italic toggle="yes">p</italic> = 0.004) levels was observed between patients treated with decoction (n = 47) and those treated with inhaled MC (n = 11), as shown in <xref rid="jox-15-00066-f001" ref-type="fig">Figure 1</xref>.</p><p>NFL and BDNF were found to be correlated with cannabinoid levels: specifically, NFL with THCA levels (<italic toggle="yes">p</italic> &#x0003c; 0.001 S = 0.572) and BDNF with 11-OH-THC, COOH-THC, COOH-THC-glucuronide, and 7-OH-CBD levels (<italic toggle="yes">p</italic> = 0.005, S = 0.367; <italic toggle="yes">p</italic> = 0.023, S = 0.307; <italic toggle="yes">p</italic> = 0.001, S = 0.447).</p></sec><sec id="sec3dot3-jox-15-00066"><title>3.3. Genetics</title><p>Single-nucleotide polymorphisms (SNPs) were found to impact cannabinoid concentrations (<xref rid="jox-15-00066-t006" ref-type="table">Table 6</xref>).</p><p>In particular, the <italic toggle="yes">COMT</italic> 680 TC/CC variant influences &#x00394;9-THC, OH-THC, COOH-THC, COOH-THC-glucuronide, and 7-OH-CBD plasma levels. For instance, the effect of the <italic toggle="yes">COMT</italic> 680 T&#x0003e;C variant on &#x00394;9-THC plasma exposure is depicted in <xref rid="jox-15-00066-f002" ref-type="fig">Figure 2</xref>.</p></sec></sec><sec sec-type="discussion" id="sec4-jox-15-00066"><title>4. Discussion</title><p>As reported in a previous study by our group, statistically significant differences in cannabinoid plasma exposure between inhaled and oral administration were found in patients with chronic pain treated with MC [<xref rid="B35-jox-15-00066" ref-type="bibr">35</xref>]. In light of this, one of the aims of the present study was to investigate the influence of cannabinoid plasma levels on inflammation-related and neurological markers in individuals treated with MC.</p><p>Plasma levels of IL-6, IL-10, and TNF-&#x003b1; were measured as markers of inflammation. Among them, IL-10 levels significantly differed between patients treated with oral and inhaled MC (<italic toggle="yes">p</italic> = 0.009), with lower IL-10 levels in patients using inhaled MC. Cannabinoids play a role in modulating cytokine production within immune cells, since they express the cannabinoid receptor [<xref rid="B36-jox-15-00066" ref-type="bibr">36</xref>]. Tan et al. [<xref rid="B37-jox-15-00066" ref-type="bibr">37</xref>] highlighted that both CBD and THC can suppress the extracellular release of pro- and anti-inflammatory cytokines in an in vitro PBMC model. Notably, treatment with 50 &#x003bc;M cannabidiol significantly reduces the secretion of IL-6 and IL-10. Consequently, higher cannabinoid concentrations, mostly reached via inhalation, are probably related to increased cytokine production.</p><p>Furthermore, a statistically significant difference in BDNF levels was observed between patients treated with oral and inhaled MC (<italic toggle="yes">p</italic> = 0.004), with higher levels detected in the latter group. A correlation between BDNF levels and some MC metabolites (11-OH-THC, COOH-THC, COOH-THC-glucuronide, and 7-OH-CBD) was highlighted, suggesting a protective role of cannabinoids. Indeed, BDNF levels in patients treated with MC (median value 1672.6 pg/mL) were higher than BDNF levels in both healthy subjects (167.1 &#x000b1; 171.2 pg/mL) and in patients with fibromyalgia (113.8 &#x000b1; 149.6 pg/mL), as reported in the literature [<xref rid="B38-jox-15-00066" ref-type="bibr">38</xref>]. BDNF is involved in neuron growth, development, and survival, both in the central and peripheral nervous system [<xref rid="B39-jox-15-00066" ref-type="bibr">39</xref>], playing a crucial role in synaptic plasticity and neurogenesis [<xref rid="B40-jox-15-00066" ref-type="bibr">40</xref>]. Reduced levels of neurotrophic factors (e.g., BDNF) were described in neurodegenerative disorders [<xref rid="B41-jox-15-00066" ref-type="bibr">41</xref>,<xref rid="B42-jox-15-00066" ref-type="bibr">42</xref>], such as Parkinson&#x02019;s disease [<xref rid="B43-jox-15-00066" ref-type="bibr">43</xref>], Alzheimer&#x02019;s disease [<xref rid="B44-jox-15-00066" ref-type="bibr">44</xref>,<xref rid="B45-jox-15-00066" ref-type="bibr">45</xref>], and multiple sclerosis [<xref rid="B46-jox-15-00066" ref-type="bibr">46</xref>,<xref rid="B47-jox-15-00066" ref-type="bibr">47</xref>]. In the literature, a decrease in BDNF plasma levels is associated with impaired brain health [<xref rid="B48-jox-15-00066" ref-type="bibr">48</xref>,<xref rid="B49-jox-15-00066" ref-type="bibr">49</xref>], whereas high levels of BDNF are associated with an improved clinical outcome in patients with schizophrenia [<xref rid="B50-jox-15-00066" ref-type="bibr">50</xref>,<xref rid="B51-jox-15-00066" ref-type="bibr">51</xref>]. THC can upregulate BDNF expression [<xref rid="B52-jox-15-00066" ref-type="bibr">52</xref>,<xref rid="B53-jox-15-00066" ref-type="bibr">53</xref>,<xref rid="B54-jox-15-00066" ref-type="bibr">54</xref>,<xref rid="B55-jox-15-00066" ref-type="bibr">55</xref>]: in fact, in our study, we found that cannabinoids may exert a significant effect on BDNF levels, especially when administered with inhalation. The upregulation of BDNF by THC could be a key mechanism underlying the neuroprotective and neuroplastic effects observed in our patients.</p><p>Regarding genetic analysis, SNPs encoding enzymes and transporters associated with cannabinoid metabolism and elimination were explored. In the literature, genetic studies suggested that <italic toggle="yes">CYP2C9</italic>*2 and *3 genotype frequencies in Caucasians are respectively &#x0003e;18% and 15&#x02013;20% [<xref rid="B29-jox-15-00066" ref-type="bibr">29</xref>,<xref rid="B56-jox-15-00066" ref-type="bibr">56</xref>]: these gene variants are associated with slower metabolism of THC compared to the <italic toggle="yes">CYP2C9*1</italic> variant [<xref rid="B29-jox-15-00066" ref-type="bibr">29</xref>]. In fact, individuals carrying mutations have higher THC concentrations than those with normal alleles (200&#x02013;300%) [<xref rid="B56-jox-15-00066" ref-type="bibr">56</xref>]. However, no significant association between CYP2C9 polymorphisms and cannabinoid plasma levels was observed in this cohort, consistent with the findings of Papastergiou et al. [<xref rid="B57-jox-15-00066" ref-type="bibr">57</xref>].</p><p>Other enzymes relevant to cannabinoid metabolism include CYP3A4 and CYP2C19: the first is implicated in THC and CBD metabolism, while CYP2C19 has an important role in the conversion of CBD in its active metabolite 7-OH-CBD [<xref rid="B58-jox-15-00066" ref-type="bibr">58</xref>], whose formation was positively correlated with enzyme activity but not with <italic toggle="yes">CYP2C19</italic> genotype [<xref rid="B58-jox-15-00066" ref-type="bibr">58</xref>]. In the literature, no association between 7-OH-CBD levels and <italic toggle="yes">CYP2C19</italic> genotype was suggested [<xref rid="B58-jox-15-00066" ref-type="bibr">58</xref>], as reported in our results.</p><p>CYP2D6, a key enzyme in the metabolism of psychotropic agents, such as antipsychotics, antidepressants, and anticonvulsants, is also expressed in the brain. Few works investigated the associations between <italic toggle="yes">CYP2D6</italic> and cannabinoids. In our analysis, the <italic toggle="yes">CYP2D6</italic> 840 CG/GG genotype was associated with lower THCA plasma concentrations compared to the CC genotype.</p><p>Regarding drug transporters, P-glycoprotein is an efflux protein belonging to the ATP-binding cassette subfamily B member 1, encoded by the <italic toggle="yes">ABCB1</italic> gene [<xref rid="B59-jox-15-00066" ref-type="bibr">59</xref>].</p><p><italic toggle="yes">ABCB1</italic> polymorphisms were studied for their role in cannabis addiction [<xref rid="B60-jox-15-00066" ref-type="bibr">60</xref>,<xref rid="B61-jox-15-00066" ref-type="bibr">61</xref>]: the <italic toggle="yes">ABCB1</italic> 3435 SNP was related to cannabis dependence [<xref rid="B29-jox-15-00066" ref-type="bibr">29</xref>,<xref rid="B62-jox-15-00066" ref-type="bibr">62</xref>]. In a study focused on cannabinoid blood levels, <italic toggle="yes">ABCB1</italic> 3435 T allele carriers had lower THC plasma concentrations than non-T carriers. However, the exact mechanisms were not clarified [<xref rid="B63-jox-15-00066" ref-type="bibr">63</xref>].</p><p><italic toggle="yes">COMT</italic> encodes for catechol-O-methyltransferase [<xref rid="B64-jox-15-00066" ref-type="bibr">64</xref>] and plays a critical role in dopamine metabolism. In the literature, COMT impacts MC response, psychosis risk, and cognitive impairment [<xref rid="B29-jox-15-00066" ref-type="bibr">29</xref>,<xref rid="B61-jox-15-00066" ref-type="bibr">61</xref>]. The role of the <italic toggle="yes">COMT</italic> Val158Met genotype in modulating THC effect on cognition and psychosis was described: high activity associated with the GG genotype (Val/Val) was related with more sensitivity to THC-induced memory impairments compared to the Met allele [<xref rid="B64-jox-15-00066" ref-type="bibr">64</xref>]. <italic toggle="yes">COMT</italic> 680 T&#x0003e;C influences all the cannabinoids quantified in the present study, except for CBD, CBDA, and THCA: in particular, &#x00394;9-THC plasma levels are higher in the TT genotype and lower in patients with the TC/CC genotype (<italic toggle="yes">p</italic> = 0.017).</p><p>This study has severe limitations: mainly the small sample size and the imbalance in the number of patients treated with oral versus inhaled MC, which may affect the broader relevance of the results. Nevertheless, as a preliminary investigation, these constraints are understandable and underscore the need for larger, more homogeneous cohorts in future studies. In addition, patient heterogeneity in terms of underlying pathology and MC dosage should be considered when interpreting the findings. Moreover, different pathologies and drug dosages were considered in the study.</p></sec><sec sec-type="conclusions" id="sec5-jox-15-00066"><title>5. Conclusions</title><p>In conclusion, this study suggests a potential impact of some genetic variants on cannabinoid plasma exposure. In addition, for the first time, a possible association between MC treatment, inflammation, and neuronal-related factors was suggested: patients treated with inhaled MC, showing higher cannabinoid concentrations, had lower IL-10 levels and higher BDNF levels. These data may help clarify the protective role of cannabinoids. Further research is needed to confirm the influence of genetic variants on cannabinoid metabolism and to explore the newly reported associations with inflammation and neuroplasticity biomarkers.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank CoQua Lab (<uri xlink:href="www.coqualab.it">www.coqualab.it</uri>) (accessed date: 5 May 2025) for its methodological support and assistance in the preparation and execution of the study and analysis.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-jox-15-00066"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/jox15030066/s1">https://www.mdpi.com/article/10.3390/jox15030066/s1</uri>, Table S1: Concomitant class of drugs administered in enrolled patients (reproduced or adapted from [<xref rid="B35-jox-15-00066" ref-type="bibr">35</xref>], with permission from publisher Alessandra Manca, 2024).</p><supplementary-material id="jox-15-00066-s001" position="float" content-type="local-data"><media xlink:href="jox-15-00066-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.M. and C.V.; methodology, F.C. and A.M.; software, J.M. and S.S.; validation, A.M., A.D.N. and A.P.; formal analysis, M.A., A.P. and J.C.; investigation, A.M. and C.V.; resources, A.D.; data curation, A.M., J.C. and C.V.; writing&#x02014;original draft preparation, A.M. and C.V.; writing&#x02014;review and editing, J.C. and A.D. visualization, N.L., D.I., D.D.C. and F.V.; supervision, J.C. and A.D.; project administration, A.M. and C.V.; funding acquisition, A.D. and J.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was performed in compliance with the Declaration of Helsinki and local review board regulations; all patients gave written informed consent, according to the local ethics committee standards (&#x0201c;Cannabis terapeutica nei pazienti affetti da dolore neuropatico: studio osservazionale&#x0201d;, approved by Ethical Committee &#x0201c;A.O.U. CITTA&#x02019; DELLA SALUTE E DELLA SCIENZA DI TORINO&#x02014;A.O. ORDINE MAURIZIANO DI TORINO&#x02014;A.S.L. CITT&#x000c0; DI TORINO&#x0201d;, n&#x000b0; 0131170 del 25/11/2022).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study. Written informed consent was obtained from the patients to publish this paper.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data is contained within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>A.M. reports a relationship with CoQua Lab srl that includes equity or stocks. A.D. reports a relationship with CoQua Lab srl that includes equity or stocks.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript: 5-HT1A: serotonin 1A receptor; 11-OH-THC: 11-Hydroxy-&#x00394;9-tetrahydrocannabinol; &#x00394;8-THC: &#x00394;8-tetrahydrocannabinol; &#x00394;9-THC: &#x00394;9-tetrahydrocannabinol; BDNF: brain-derived neurotropic factor; CB<sub>1</sub>: Cannabinoid-receptor type 1; CB<sub>2</sub>: Cannabinoid-receptor type 2; CBD: cannabidiol; CBDA: cannabidiolic acid; CBN: cannabinol; CBRs: cannabinoid receptors; CNS: central nervous system; CYP: cytochrome; GPCRs: G-protein-coupled receptors; IL: interleukin; PD: pharmacodynamic; PK: pharmacokinetics; PNS: peripheral nervous system; PPAR: peroxisome proliferator-activated receptors; SNPs: single-nucleotide polymorphisms; TDM: therapeutic drug monitoring; THCA: tetrahydrocannabinolic acid; THC-COOH-: 11-Nor-9carboxy-&#x00394;9-tetrahydrocannabinol; TNF-&#x003b1;: tumor necrosis factor &#x003b1;; TRPV-1: transient receptor potential vanilloid receptor; UHPLC-MS/MS: ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.</p></glossary><ref-list><title>References</title><ref id="B1-jox-15-00066"><label>1.</label><element-citation publication-type="webpage"><article-title>WHO</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis" ext-link-type="uri">https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-09">(accessed on 9 November 2023)</date-in-citation></element-citation></ref><ref id="B2-jox-15-00066"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pisanti</surname><given-names>S.</given-names></name>
<name><surname>Bifulco</surname><given-names>M.</given-names></name>
</person-group><article-title>Medical Cannabis: A plurimillennial history of an evergreen</article-title><source>J. Cell Physiol.</source><year>2018</year><volume>234</volume><fpage>8342</fpage><lpage>8351</lpage><pub-id pub-id-type="doi">10.1002/jcp.27725</pub-id><pub-id pub-id-type="pmid">30417354</pub-id>
</element-citation></ref><ref id="B3-jox-15-00066"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okazaki</surname><given-names>H.</given-names></name>
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Momohara</surname><given-names>A.</given-names></name>
<name><surname>Eguchi</surname><given-names>S.</given-names></name>
<name><surname>Okamoto</surname><given-names>T.</given-names></name>
<name><surname>Yanagisawa</surname><given-names>S.</given-names></name>
<name><surname>Okubo</surname><given-names>S.</given-names></name>
<name><surname>Kiyonage</surname><given-names>J.</given-names></name>
</person-group><article-title>Early Holocene coastal environment change in ferred from deposits at Okinoshima archeological site, Boso Peninsula, central Japan</article-title><source>Quat. Int.</source><year>2011</year><volume>230</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.quaint.2009.11.002</pub-id></element-citation></ref><ref id="B4-jox-15-00066"><label>4.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>G.U.</collab>
</person-group><article-title>Decreto Ministeriale 9 November 2015. Funzioni di Organisimo Statale per la Cannabis Previsto Dagli Articoli 23 e 28 Della Convenzione Unica Sugli Stupefacenti del 1961, Come Modificata Nel 1972</article-title><comment>Available online: <ext-link xlink:href="https://www.epicentro.iss.it/farmaci/pdf/Decreto%20uso%20medico%20Cannabis%20(GU%2030.11.2015)%20" ext-link-type="uri">https://www.epicentro.iss.it/farmaci/pdf/Decreto%20uso%20medico%20Cannabis%20(GU%2030.11.2015)%20</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-03">(accessed on 3 March 2025)</date-in-citation></element-citation></ref><ref id="B5-jox-15-00066"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aizpurua-Olaizola</surname><given-names>O.</given-names></name>
<name><surname>Elezgarai</surname><given-names>I.</given-names></name>
<name><surname>Rico-Barrio</surname><given-names>I.</given-names></name>
<name><surname>Zarandona</surname><given-names>I.</given-names></name>
<name><surname>Etxebarria</surname><given-names>N.</given-names></name>
<name><surname>Usobiaga</surname><given-names>A.</given-names></name>
</person-group><article-title>Targeting the endocannabinoid system: Future therapeutic strategies</article-title><source>Drug Discov. Today</source><year>2016</year><volume>22</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.08.005</pub-id><pub-id pub-id-type="pmid">27554802</pub-id>
</element-citation></ref><ref id="B6-jox-15-00066"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Battista</surname><given-names>N.</given-names></name>
<name><surname>Di Tommaso</surname><given-names>M.</given-names></name>
<name><surname>Bari</surname><given-names>M.</given-names></name>
<name><surname>Maccarrone</surname><given-names>M.</given-names></name>
</person-group><article-title>The endocannabinoid system: An overview</article-title><source>Front. Behav. Neurosci.</source><year>2012</year><volume>6</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.3389/fnbeh.2012.00009</pub-id><pub-id pub-id-type="pmid">22457644</pub-id>
</element-citation></ref><ref id="B7-jox-15-00066"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lowe</surname><given-names>H.</given-names></name>
<name><surname>Toyang</surname><given-names>N.</given-names></name>
<name><surname>Steele</surname><given-names>B.</given-names></name>
<name><surname>Bryant</surname><given-names>J.</given-names></name>
<name><surname>Ngwa</surname><given-names>W.</given-names></name>
</person-group><article-title>The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>9472</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22179472</pub-id><pub-id pub-id-type="pmid">34502379</pub-id>
</element-citation></ref><ref id="B8-jox-15-00066"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pacher</surname><given-names>P.</given-names></name>
<name><surname>Batkai</surname><given-names>S.</given-names></name>
<name><surname>Kunos</surname><given-names>G.</given-names></name>
</person-group><article-title>The endocannabinoid system as an emerging target of pharmacotherapy</article-title><source>Pharmacol. Rev.</source><year>2006</year><volume>58</volume><fpage>389</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1124/pr.58.3.2</pub-id><pub-id pub-id-type="pmid">16968947</pub-id>
</element-citation></ref><ref id="B9-jox-15-00066"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eid</surname><given-names>B.G.</given-names></name>
</person-group><article-title>Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle</article-title><source>J. Microsc. Ultrastruct.</source><year>2018</year><volume>6</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.4103/JMAU.JMAU_42_18</pub-id><pub-id pub-id-type="pmid">30464888</pub-id>
</element-citation></ref><ref id="B10-jox-15-00066"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendizabal</surname><given-names>V.E.</given-names></name>
<name><surname>Adler-Graschinsky</surname><given-names>E.</given-names></name>
</person-group><article-title>Cannabinoids as therapeutic agents in cardiovascular disease: A tale of passions and illusions</article-title><source>Br. J. Pharmacol.</source><year>2007</year><volume>151</volume><fpage>427</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707261</pub-id><pub-id pub-id-type="pmid">17450170</pub-id>
</element-citation></ref><ref id="B11-jox-15-00066"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borowska</surname><given-names>M.</given-names></name>
<name><surname>Czarnywojtek</surname><given-names>A.</given-names></name>
<name><surname>Sawicka-Gutaj</surname><given-names>N.</given-names></name>
<name><surname>Wolinski</surname><given-names>K.</given-names></name>
<name><surname>Plazinska</surname><given-names>M.T.</given-names></name>
<name><surname>Mikolajczak</surname><given-names>P.</given-names></name>
<name><surname>Ruchala</surname><given-names>M.</given-names></name>
</person-group><article-title>The effects of cannabinoids on the endocrine system</article-title><source>Endokrynol. Pol.</source><year>2018</year><volume>69</volume><fpage>705</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.5603/EP.a2018.0072</pub-id><pub-id pub-id-type="pmid">30618031</pub-id>
</element-citation></ref><ref id="B12-jox-15-00066"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parsons</surname><given-names>L.H.</given-names></name>
<name><surname>Hurd</surname><given-names>Y.L.</given-names></name>
</person-group><article-title>Endocannabinoid signalling in reward and addiction</article-title><source>Nat. Rev. Neurosci.</source><year>2015</year><volume>16</volume><fpage>579</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/nrn4004</pub-id><pub-id pub-id-type="pmid">26373473</pub-id>
</element-citation></ref><ref id="B13-jox-15-00066"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whiteside</surname><given-names>G.T.</given-names></name>
<name><surname>Lee</surname><given-names>G.P.</given-names></name>
<name><surname>Valenzano</surname><given-names>K.J.</given-names></name>
</person-group><article-title>The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists</article-title><source>Curr. Med. Chem.</source><year>2007</year><volume>14</volume><fpage>917</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.2174/092986707780363023</pub-id><pub-id pub-id-type="pmid">17430144</pub-id>
</element-citation></ref><ref id="B14-jox-15-00066"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romero</surname><given-names>T.R.</given-names></name>
<name><surname>Resende</surname><given-names>L.C.</given-names></name>
<name><surname>Guzzo</surname><given-names>L.S.</given-names></name>
<name><surname>Duarte</surname><given-names>I.D.</given-names></name>
</person-group><article-title>CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system</article-title><source>Anesth. Analg.</source><year>2013</year><volume>116</volume><fpage>463</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1213/ANE.0b013e3182707859</pub-id><pub-id pub-id-type="pmid">23302980</pub-id>
</element-citation></ref><ref id="B15-jox-15-00066"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chia</surname><given-names>J.S.M.</given-names></name>
<name><surname>Farouk</surname><given-names>A.A.O.</given-names></name>
<name><surname>Mohamad</surname><given-names>T.</given-names></name>
<name><surname>Sulaiman</surname><given-names>M.R.</given-names></name>
<name><surname>Zakaria</surname><given-names>H.</given-names></name>
<name><surname>Hassan</surname><given-names>N.I.</given-names></name>
<name><surname>Perimal</surname><given-names>E.K.</given-names></name>
</person-group><article-title>Zerumbone Ameliorates Neuropathic Pain Symptoms via Cannabinoid and PPAR Receptors Using In Vivo and In Silico Models</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>3849</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26133849</pub-id><pub-id pub-id-type="pmid">34202590</pub-id>
</element-citation></ref><ref id="B16-jox-15-00066"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anand</surname><given-names>U.</given-names></name>
<name><surname>Otto</surname><given-names>W.R.</given-names></name>
<name><surname>Sanchez-Herrera</surname><given-names>D.</given-names></name>
<name><surname>Facer</surname><given-names>P.</given-names></name>
<name><surname>Yiangou</surname><given-names>Y.</given-names></name>
<name><surname>Korchev</surname><given-names>Y.</given-names></name>
<name><surname>Birch</surname><given-names>R.</given-names></name>
<name><surname>Benham</surname><given-names>C.</given-names></name>
<name><surname>Bountra</surname><given-names>C.</given-names></name>
<name><surname>Chessell</surname><given-names>I.P.</given-names></name>
<etal/>
</person-group><article-title>Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons</article-title><source>Pain</source><year>2008</year><volume>138</volume><fpage>667</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2008.06.007</pub-id><pub-id pub-id-type="pmid">18692962</pub-id>
</element-citation></ref><ref id="B17-jox-15-00066"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahn</surname><given-names>E.J.</given-names></name>
<name><surname>Hohmann</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside</article-title><source>Neurotherapeutics</source><year>2009</year><volume>6</volume><fpage>713</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.nurt.2009.08.002</pub-id><pub-id pub-id-type="pmid">19789075</pub-id>
</element-citation></ref><ref id="B18-jox-15-00066"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shohami</surname><given-names>E.</given-names></name>
<name><surname>Cohen-Yeshurun</surname><given-names>A.</given-names></name>
<name><surname>Magid</surname><given-names>L.</given-names></name>
<name><surname>Algali</surname><given-names>M.</given-names></name>
<name><surname>Mechoulam</surname><given-names>R.</given-names></name>
</person-group><article-title>Endocannabinoids and traumatic brain injury</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>163</volume><fpage>1402</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01343.x</pub-id><pub-id pub-id-type="pmid">21418185</pub-id>
</element-citation></ref><ref id="B19-jox-15-00066"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagarkatti</surname><given-names>P.</given-names></name>
<name><surname>Pandey</surname><given-names>R.</given-names></name>
<name><surname>Rieder</surname><given-names>S.A.</given-names></name>
<name><surname>Hegde</surname><given-names>V.L.</given-names></name>
<name><surname>Nagarkatti</surname><given-names>M.</given-names></name>
</person-group><article-title>Cannabinoids as novel anti-inflammatory drugs</article-title><source>Future Med. Chem.</source><year>2009</year><volume>1</volume><fpage>1333</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.4155/fmc.09.93</pub-id><pub-id pub-id-type="pmid">20191092</pub-id>
</element-citation></ref><ref id="B20-jox-15-00066"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Staton</surname><given-names>P.C.</given-names></name>
<name><surname>Hatcher</surname><given-names>J.P.</given-names></name>
<name><surname>Walker</surname><given-names>D.J.</given-names></name>
<name><surname>Morrison</surname><given-names>A.D.</given-names></name>
<name><surname>Shapland</surname><given-names>E.M.</given-names></name>
<name><surname>Hughes</surname><given-names>J.P.</given-names></name>
<name><surname>Chong</surname><given-names>E.</given-names></name>
<name><surname>Mander</surname><given-names>P.K.</given-names></name>
<name><surname>Green</surname><given-names>P.J.</given-names></name>
<name><surname>Billinton</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain</article-title><source>Pain</source><year>2008</year><volume>139</volume><fpage>225</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2008.04.006</pub-id><pub-id pub-id-type="pmid">18502582</pub-id>
</element-citation></ref><ref id="B21-jox-15-00066"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burstein</surname><given-names>S.</given-names></name>
</person-group><article-title>Cannabidiol (CBD) and its analogs: A review of their effects on inflammation</article-title><source>Bioorg. Med. Chem.</source><year>2015</year><volume>23</volume><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2015.01.059</pub-id><pub-id pub-id-type="pmid">25703248</pub-id>
</element-citation></ref><ref id="B22-jox-15-00066"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porter</surname><given-names>B.E.</given-names></name>
<name><surname>Jacobson</surname><given-names>C.</given-names></name>
</person-group><article-title>Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy</article-title><source>Epilepsy Behav.</source><year>2013</year><volume>29</volume><fpage>574</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2013.08.037</pub-id><pub-id pub-id-type="pmid">24237632</pub-id>
</element-citation></ref><ref id="B23-jox-15-00066"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>T.K.S.</given-names></name>
<name><surname>Coughlan</surname><given-names>C.</given-names></name>
<name><surname>Heyn</surname><given-names>P.C.</given-names></name>
<name><surname>Tagawa</surname><given-names>A.</given-names></name>
<name><surname>Carollo</surname><given-names>J.J.</given-names></name>
<name><surname>Kua</surname><given-names>E.H.</given-names></name>
<name><surname>Mahendran</surname><given-names>R.</given-names></name>
</person-group><article-title>Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: A case-control study</article-title><source>Aging</source><year>2021</year><volume>13</volume><fpage>22666</fpage><lpage>22689</lpage><pub-id pub-id-type="doi">10.18632/aging.203598</pub-id><pub-id pub-id-type="pmid">34607976</pub-id>
</element-citation></ref><ref id="B24-jox-15-00066"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>G.</given-names></name>
<name><surname>Beiser</surname><given-names>A.S.</given-names></name>
<name><surname>Choi</surname><given-names>S.H.</given-names></name>
<name><surname>Preis</surname><given-names>S.R.</given-names></name>
<name><surname>Chen</surname><given-names>T.C.</given-names></name>
<name><surname>Vorgas</surname><given-names>D.</given-names></name>
<name><surname>Au</surname><given-names>R.</given-names></name>
<name><surname>Pikula</surname><given-names>A.</given-names></name>
<name><surname>Wolf</surname><given-names>P.A.</given-names></name>
<name><surname>DeStefano</surname><given-names>A.L.</given-names></name>
<etal/>
</person-group><article-title>Serum brain-derived neurotrophic factor and the risk for dementia: The Framingham Heart Study</article-title><source>JAMA Neurol.</source><year>2014</year><volume>71</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2013.4781</pub-id><pub-id pub-id-type="pmid">24276217</pub-id>
</element-citation></ref><ref id="B25-jox-15-00066"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di-Bonaventura</surname><given-names>S.</given-names></name>
<name><surname>Gurdiel-Alvarez</surname><given-names>F.</given-names></name>
<name><surname>Reina-Varona</surname><given-names>A.</given-names></name>
<name><surname>Pacheco-Barrios</surname><given-names>K.</given-names></name>
<name><surname>Molina-Alvarez</surname><given-names>M.</given-names></name>
<name><surname>Fernandez-Carnero</surname><given-names>J.</given-names></name>
<name><surname>Ferrer-Pena</surname><given-names>R.</given-names></name>
</person-group><article-title>Differences in Plasma BDNF Levels Between Chronic Primary Musculoskeletal Pain, Fibromyalgia Syndrome, and Asymptomatic Subjects: A Cross-Sectional Study</article-title><source>Biol. Res. Nurs.</source><year>2025</year><elocation-id>10998004251313741</elocation-id><pub-id pub-id-type="doi">10.1177/10998004251313741</pub-id><pub-id pub-id-type="pmid">39789935</pub-id>
</element-citation></ref><ref id="B26-jox-15-00066"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hock</surname><given-names>C.</given-names></name>
<name><surname>Heese</surname><given-names>K.</given-names></name>
<name><surname>Hulette</surname><given-names>C.</given-names></name>
<name><surname>Rosenberg</surname><given-names>C.</given-names></name>
<name><surname>Otten</surname><given-names>U.</given-names></name>
</person-group><article-title>Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas</article-title><source>Arch. Neurol.</source><year>2000</year><volume>57</volume><fpage>846</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1001/archneur.57.6.846</pub-id><pub-id pub-id-type="pmid">10867782</pub-id>
</element-citation></ref><ref id="B27-jox-15-00066"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merighi</surname><given-names>A.</given-names></name>
</person-group><article-title>Brain-Derived Neurotrophic Factor, Nociception, and Pain</article-title><source>Biomolecules</source><year>2024</year><volume>14</volume><elocation-id>539</elocation-id><pub-id pub-id-type="doi">10.3390/biom14050539</pub-id><pub-id pub-id-type="pmid">38785946</pub-id>
</element-citation></ref><ref id="B28-jox-15-00066"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>H.Y.</given-names></name>
<name><surname>Hendrix</surname><given-names>J.</given-names></name>
<name><surname>Schabrun</surname><given-names>S.</given-names></name>
<name><surname>Wyns</surname><given-names>A.</given-names></name>
<name><surname>Campenhout</surname><given-names>J.V.</given-names></name>
<name><surname>Nijs</surname><given-names>J.</given-names></name>
<name><surname>Polli</surname><given-names>A.</given-names></name>
</person-group><article-title>The Role of the Brain-Derived Neurotrophic Factor in Chronic Pain: Links to Central Sensitization and Neuroinflammation</article-title><source>Biomolecules</source><year>2024</year><volume>14</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3390/biom14010071</pub-id><pub-id pub-id-type="pmid">38254671</pub-id>
</element-citation></ref><ref id="B29-jox-15-00066"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babayeva</surname><given-names>M.</given-names></name>
<name><surname>Loewy</surname><given-names>Z.G.</given-names></name>
</person-group><article-title>Cannabis Pharmacogenomics: A Path to Personalized Medicine</article-title><source>Curr. Issues Mol. Biol.</source><year>2023</year><volume>45</volume><fpage>3479</fpage><lpage>3514</lpage><pub-id pub-id-type="doi">10.3390/cimb45040228</pub-id><pub-id pub-id-type="pmid">37185752</pub-id>
</element-citation></ref><ref id="B30-jox-15-00066"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hryhorowicz</surname><given-names>S.</given-names></name>
<name><surname>Walczak</surname><given-names>M.</given-names></name>
<name><surname>Zakerska-Banaszak</surname><given-names>O.</given-names></name>
<name><surname>Slomski</surname><given-names>R.</given-names></name>
<name><surname>Skrzypczak-Zielinska</surname><given-names>M.</given-names></name>
</person-group><article-title>Pharmacogenetics of Cannabinoids</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>2018</year><volume>43</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s13318-017-0416-z</pub-id><pub-id pub-id-type="pmid">28534260</pub-id>
</element-citation></ref><ref id="B31-jox-15-00066"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huestis</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Human cannabinoid pharmacokinetics</article-title><source>Chem. Biodivers.</source><year>2007</year><volume>4</volume><fpage>1770</fpage><lpage>1804</lpage><pub-id pub-id-type="doi">10.1002/cbdv.200790152</pub-id><pub-id pub-id-type="pmid">17712819</pub-id>
</element-citation></ref><ref id="B32-jox-15-00066"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lodzki</surname><given-names>M.</given-names></name>
<name><surname>Godin</surname><given-names>B.</given-names></name>
<name><surname>Rakou</surname><given-names>L.</given-names></name>
<name><surname>Mechoulam</surname><given-names>R.</given-names></name>
<name><surname>Gallily</surname><given-names>R.</given-names></name>
<name><surname>Touitou</surname><given-names>E.</given-names></name>
</person-group><article-title>Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model</article-title><source>J. Control Release</source><year>2003</year><volume>93</volume><fpage>377</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2003.09.001</pub-id><pub-id pub-id-type="pmid">14644587</pub-id>
</element-citation></ref><ref id="B33-jox-15-00066"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khalil</surname><given-names>H.</given-names></name>
</person-group><article-title>Medicinal cannabis: Presenting possible treatment modalities for the future</article-title><source>Int. J. Evid. Based Healthc.</source><year>2018</year><volume>16</volume><fpage>81</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/XEB.0000000000000145</pub-id><pub-id pub-id-type="pmid">29870436</pub-id>
</element-citation></ref><ref id="B34-jox-15-00066"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manca</surname><given-names>A.</given-names></name>
<name><surname>Chiara</surname><given-names>F.</given-names></name>
<name><surname>Mula</surname><given-names>J.</given-names></name>
<name><surname>Palermiti</surname><given-names>A.</given-names></name>
<name><surname>Maiese</surname><given-names>D.</given-names></name>
<name><surname>Zeaiter</surname><given-names>S.</given-names></name>
<name><surname>De Nicolo</surname><given-names>A.</given-names></name>
<name><surname>Imperiale</surname><given-names>D.</given-names></name>
<name><surname>De Filippis</surname><given-names>G.</given-names></name>
<name><surname>Vischia</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>A new UHPLC-MS/MS method for cannabinoids determination in human plasma: A clinical tool for therapeutic drug monitoring</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>156</volume><elocation-id>113899</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113899</pub-id><pub-id pub-id-type="pmid">36279720</pub-id>
</element-citation></ref><ref id="B35-jox-15-00066"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manca</surname><given-names>A.</given-names></name>
<name><surname>Valz</surname><given-names>C.</given-names></name>
<name><surname>Chiara</surname><given-names>F.</given-names></name>
<name><surname>Mula</surname><given-names>J.</given-names></name>
<name><surname>Palermiti</surname><given-names>A.</given-names></name>
<name><surname>Billi</surname><given-names>M.</given-names></name>
<name><surname>Antonucci</surname><given-names>M.</given-names></name>
<name><surname>Nicolo</surname><given-names>A.</given-names></name>
<name><surname>Luxardo</surname><given-names>N.</given-names></name>
<name><surname>Imperiale</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>175</volume><elocation-id>116686</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116686</pub-id><pub-id pub-id-type="pmid">38713939</pub-id>
</element-citation></ref><ref id="B36-jox-15-00066"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joffre</surname><given-names>J.</given-names></name>
<name><surname>Yeh</surname><given-names>C.C.</given-names></name>
<name><surname>Wong</surname><given-names>E.</given-names></name>
<name><surname>Thete</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>F.</given-names></name>
<name><surname>Zlatanova</surname><given-names>I.</given-names></name>
<name><surname>Lloyd</surname><given-names>E.</given-names></name>
<name><surname>Kobzik</surname><given-names>L.</given-names></name>
<name><surname>Legrand</surname><given-names>M.</given-names></name>
<name><surname>Hellman</surname><given-names>J.</given-names></name>
</person-group><article-title>Activation of CB(1)R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury</article-title><source>J. Immunol.</source><year>2020</year><volume>204</volume><fpage>3339</fpage><lpage>3350</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000213</pub-id><pub-id pub-id-type="pmid">32385136</pub-id>
</element-citation></ref><ref id="B37-jox-15-00066"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>K.B.C.</given-names></name>
<name><surname>Alexander</surname><given-names>H.D.</given-names></name>
<name><surname>Linden</surname><given-names>J.</given-names></name>
<name><surname>Murray</surname><given-names>E.K.</given-names></name>
<name><surname>Gibson</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Anti-inflammatory effects of phytocannabinoids and terpenes on inflamed Tregs and Th17 cells in vitro</article-title><source>Exp. Mol. Pathol.</source><year>2024</year><volume>139</volume><fpage>104924</fpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2024.104924</pub-id><pub-id pub-id-type="pmid">39208564</pub-id>
</element-citation></ref><ref id="B38-jox-15-00066"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haas</surname><given-names>L.</given-names></name>
<name><surname>Portela</surname><given-names>L.V.</given-names></name>
<name><surname>Bohmer</surname><given-names>A.E.</given-names></name>
<name><surname>Oses</surname><given-names>J.P.</given-names></name>
<name><surname>Lara</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia</article-title><source>Neurochem. Res.</source><year>2010</year><volume>35</volume><fpage>830</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1007/s11064-010-0129-z</pub-id><pub-id pub-id-type="pmid">20119637</pub-id>
</element-citation></ref><ref id="B39-jox-15-00066"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Binder</surname><given-names>D.K.</given-names></name>
<name><surname>Scharfman</surname><given-names>H.E.</given-names></name>
</person-group><article-title>Brain-derived neurotrophic factor</article-title><source>Growth Factors</source><year>2004</year><volume>22</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1080/08977190410001723308</pub-id><pub-id pub-id-type="pmid">15518235</pub-id>
</element-citation></ref><ref id="B40-jox-15-00066"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>B.</given-names></name>
<name><surname>Nagappan</surname><given-names>G.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
</person-group><article-title>BDNF and synaptic plasticity, cognitive function, and dysfunction</article-title><source>Handb. Exp. Pharmacol.</source><year>2014</year><volume>220</volume><fpage>223</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-45106-5_9</pub-id><pub-id pub-id-type="pmid">24668475</pub-id>
</element-citation></ref><ref id="B41-jox-15-00066"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blesch</surname><given-names>A.</given-names></name>
</person-group><article-title>Neurotrophic factors in neurodegeneration</article-title><source>Brain Pathol.</source><year>2006</year><volume>16</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2006.00036.x</pub-id><pub-id pub-id-type="pmid">17107599</pub-id>
</element-citation></ref><ref id="B42-jox-15-00066"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weis</surname><given-names>J.</given-names></name>
<name><surname>Saxena</surname><given-names>S.</given-names></name>
<name><surname>Evangelopoulos</surname><given-names>M.E.</given-names></name>
<name><surname>Kruttgen</surname><given-names>A.</given-names></name>
</person-group><article-title>Trophic factors in neurodegenerative disorders</article-title><source>IUBMB Life</source><year>2003</year><volume>55</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1080/1521654031000153021</pub-id><pub-id pub-id-type="pmid">12938738</pub-id>
</element-citation></ref><ref id="B43-jox-15-00066"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janakiraman</surname><given-names>U.</given-names></name>
<name><surname>Manivasagam</surname><given-names>T.</given-names></name>
<name><surname>Justin Thenmozhi</surname><given-names>A.</given-names></name>
<name><surname>Dhanalakshmi</surname><given-names>C.</given-names></name>
<name><surname>Essa</surname><given-names>M.M.</given-names></name>
<name><surname>Song</surname><given-names>B.J.</given-names></name>
<name><surname>Guillemin</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson&#x02019;s disease</article-title><source>Physiol. Behav.</source><year>2017</year><volume>173</volume><fpage>132</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2017.01.046</pub-id><pub-id pub-id-type="pmid">28185878</pub-id>
</element-citation></ref><ref id="B44-jox-15-00066"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima Giacobbo</surname><given-names>B.</given-names></name>
<name><surname>Doorduin</surname><given-names>J.</given-names></name>
<name><surname>Klein</surname><given-names>H.C.</given-names></name>
<name><surname>Dierckx</surname><given-names>R.</given-names></name>
<name><surname>Bromberg</surname><given-names>E.</given-names></name>
<name><surname>de Vries</surname><given-names>E.F.J.</given-names></name>
</person-group><article-title>Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation</article-title><source>Mol. Neurobiol.</source><year>2018</year><volume>56</volume><fpage>3295</fpage><lpage>3312</lpage><pub-id pub-id-type="doi">10.1007/s12035-018-1283-6</pub-id><pub-id pub-id-type="pmid">30117106</pub-id>
</element-citation></ref><ref id="B45-jox-15-00066"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>S.</given-names></name>
<name><surname>Wuu</surname><given-names>J.</given-names></name>
<name><surname>Mufson</surname><given-names>E.J.</given-names></name>
<name><surname>Fahnestock</surname><given-names>M.</given-names></name>
</person-group><article-title>Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer&#x02019;s disease</article-title><source>J. Neurochem.</source><year>2005</year><volume>93</volume><fpage>1412</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03135.x</pub-id><pub-id pub-id-type="pmid">15935057</pub-id>
</element-citation></ref><ref id="B46-jox-15-00066"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azoulay</surname><given-names>D.</given-names></name>
<name><surname>Urshansky</surname><given-names>N.</given-names></name>
<name><surname>Karni</surname><given-names>A.</given-names></name>
</person-group><article-title>Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection</article-title><source>J. Neuroimmunol.</source><year>2008</year><volume>195</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.01.010</pub-id><pub-id pub-id-type="pmid">18329726</pub-id>
</element-citation></ref><ref id="B47-jox-15-00066"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patanella</surname><given-names>A.K.</given-names></name>
<name><surname>Zinno</surname><given-names>M.</given-names></name>
<name><surname>Quaranta</surname><given-names>D.</given-names></name>
<name><surname>Nociti</surname><given-names>V.</given-names></name>
<name><surname>Frisullo</surname><given-names>G.</given-names></name>
<name><surname>Gainotti</surname><given-names>G.</given-names></name>
<name><surname>Tonali</surname><given-names>P.A.</given-names></name>
<name><surname>Batocchi</surname><given-names>A.P.</given-names></name>
<name><surname>Marra</surname><given-names>C.</given-names></name>
</person-group><article-title>Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients</article-title><source>J. Neurosci. Res.</source><year>2010</year><volume>88</volume><fpage>1106</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1002/jnr.22276</pub-id><pub-id pub-id-type="pmid">19885866</pub-id>
</element-citation></ref><ref id="B48-jox-15-00066"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almeida</surname><given-names>R.D.</given-names></name>
<name><surname>Manadas</surname><given-names>B.J.</given-names></name>
<name><surname>Melo</surname><given-names>C.V.</given-names></name>
<name><surname>Gomes</surname><given-names>J.R.</given-names></name>
<name><surname>Mendes</surname><given-names>C.S.</given-names></name>
<name><surname>Graos</surname><given-names>M.M.</given-names></name>
<name><surname>Carvalho</surname><given-names>R.F.</given-names></name>
<name><surname>Carvalho</surname><given-names>A.P.</given-names></name>
<name><surname>Duarte</surname><given-names>C.B.</given-names></name>
</person-group><article-title>Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways</article-title><source>Cell Death Differ.</source><year>2005</year><volume>12</volume><fpage>1329</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401662</pub-id><pub-id pub-id-type="pmid">15905876</pub-id>
</element-citation></ref><ref id="B49-jox-15-00066"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miranda</surname><given-names>M.</given-names></name>
<name><surname>Morici</surname><given-names>J.F.</given-names></name>
<name><surname>Zanoni</surname><given-names>M.B.</given-names></name>
<name><surname>Bekinschtein</surname><given-names>P.</given-names></name>
</person-group><article-title>Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain</article-title><source>Front. Cell Neurosci.</source><year>2019</year><volume>13</volume><elocation-id>363</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2019.00363</pub-id><pub-id pub-id-type="pmid">31440144</pub-id>
</element-citation></ref><ref id="B50-jox-15-00066"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asevedo</surname><given-names>E.</given-names></name>
<name><surname>Gadelha</surname><given-names>A.</given-names></name>
<name><surname>Noto</surname><given-names>C.</given-names></name>
<name><surname>Mansur</surname><given-names>R.B.</given-names></name>
<name><surname>Zugman</surname><given-names>A.</given-names></name>
<name><surname>Belangero</surname><given-names>S.I.</given-names></name>
<name><surname>Berberian</surname><given-names>A.A.</given-names></name>
<name><surname>Scarpato</surname><given-names>B.S.</given-names></name>
<name><surname>Leclerc</surname><given-names>E.</given-names></name>
<name><surname>Teixeira</surname><given-names>A.L.</given-names></name>
<etal/>
</person-group><article-title>Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia</article-title><source>J. Psychiatr. Res.</source><year>2013</year><volume>47</volume><fpage>1376</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.032</pub-id><pub-id pub-id-type="pmid">23806580</pub-id>
</element-citation></ref><ref id="B51-jox-15-00066"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carlino</surname><given-names>D.</given-names></name>
<name><surname>Leone</surname><given-names>E.</given-names></name>
<name><surname>Di Cola</surname><given-names>F.</given-names></name>
<name><surname>Baj</surname><given-names>G.</given-names></name>
<name><surname>Marin</surname><given-names>R.</given-names></name>
<name><surname>Dinelli</surname><given-names>G.</given-names></name>
<name><surname>Tongiorgi</surname><given-names>E.</given-names></name>
<name><surname>De Vanna</surname><given-names>M.</given-names></name>
</person-group><article-title>Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia</article-title><source>J. Psychiatr. Res.</source><year>2011</year><volume>45</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2010.06.012</pub-id><pub-id pub-id-type="pmid">20630543</pub-id>
</element-citation></ref><ref id="B52-jox-15-00066"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segal-Gavish</surname><given-names>H.</given-names></name>
<name><surname>Gazit</surname><given-names>N.</given-names></name>
<name><surname>Barhum</surname><given-names>Y.</given-names></name>
<name><surname>Ben-Zur</surname><given-names>T.</given-names></name>
<name><surname>Taler</surname><given-names>M.</given-names></name>
<name><surname>Hornfeld</surname><given-names>S.H.</given-names></name>
<name><surname>Gil-Ad</surname><given-names>I.</given-names></name>
<name><surname>Weizman</surname><given-names>A.</given-names></name>
<name><surname>Slutsky</surname><given-names>I.</given-names></name>
<name><surname>Niwa</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>2462</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx139</pub-id><pub-id pub-id-type="pmid">28402427</pub-id>
</element-citation></ref><ref id="B53-jox-15-00066"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butovsky</surname><given-names>E.</given-names></name>
<name><surname>Juknat</surname><given-names>A.</given-names></name>
<name><surname>Goncharov</surname><given-names>I.</given-names></name>
<name><surname>Elbaz</surname><given-names>J.</given-names></name>
<name><surname>Eilam</surname><given-names>R.</given-names></name>
<name><surname>Zangen</surname><given-names>A.</given-names></name>
<name><surname>Vogel</surname><given-names>Z.</given-names></name>
</person-group><article-title>In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol</article-title><source>J. Neurochem.</source><year>2005</year><volume>93</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03074.x</pub-id><pub-id pub-id-type="pmid">15857384</pub-id>
</element-citation></ref><ref id="B54-jox-15-00066"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blazquez</surname><given-names>C.</given-names></name>
<name><surname>Chiarlone</surname><given-names>A.</given-names></name>
<name><surname>Bellocchio</surname><given-names>L.</given-names></name>
<name><surname>Resel</surname><given-names>E.</given-names></name>
<name><surname>Pruunsild</surname><given-names>P.</given-names></name>
<name><surname>Garcia-Rincon</surname><given-names>D.</given-names></name>
<name><surname>Sendtner</surname><given-names>M.</given-names></name>
<name><surname>Timmusk</surname><given-names>T.</given-names></name>
<name><surname>Lutz</surname><given-names>B.</given-names></name>
<name><surname>Galve-Roperh</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway</article-title><source>Cell Death Differ.</source><year>2015</year><volume>22</volume><fpage>1618</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1038/cdd.2015.11</pub-id><pub-id pub-id-type="pmid">25698444</pub-id>
</element-citation></ref><ref id="B55-jox-15-00066"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derkinderen</surname><given-names>P.</given-names></name>
<name><surname>Valjent</surname><given-names>E.</given-names></name>
<name><surname>Toutant</surname><given-names>M.</given-names></name>
<name><surname>Corvol</surname><given-names>J.C.</given-names></name>
<name><surname>Enslen</surname><given-names>H.</given-names></name>
<name><surname>Ledent</surname><given-names>C.</given-names></name>
<name><surname>Trzaskos</surname><given-names>J.</given-names></name>
<name><surname>Caboche</surname><given-names>J.</given-names></name>
<name><surname>Girault</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus</article-title><source>J. Neurosci.</source><year>2003</year><volume>23</volume><fpage>2371</fpage><lpage>2382</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-06-02371.2003</pub-id><pub-id pub-id-type="pmid">12657697</pub-id>
</element-citation></ref><ref id="B56-jox-15-00066"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirota</surname><given-names>T.</given-names></name>
<name><surname>Eguchi</surname><given-names>S.</given-names></name>
<name><surname>Ieiri</surname><given-names>I.</given-names></name>
</person-group><article-title>Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs</article-title><source>Drug Metab. Pharmacokinet.</source><year>2012</year><volume>28</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-12-RV-085</pub-id><pub-id pub-id-type="pmid">23165865</pub-id>
</element-citation></ref><ref id="B57-jox-15-00066"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papastergiou</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Sterling</surname><given-names>C.</given-names></name>
<name><surname>van den Bemt</surname><given-names>B.</given-names></name>
</person-group><article-title>Pharmacogenetic-guided cannabis usage in the community pharmacy: Evaluation of a pilot program</article-title><source>J. Cannabis Res.</source><year>2020</year><volume>2</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s42238-020-00033-1</pub-id><pub-id pub-id-type="pmid">33526106</pub-id>
</element-citation></ref><ref id="B58-jox-15-00066"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beers</surname><given-names>J.L.</given-names></name>
<name><surname>Fu</surname><given-names>D.</given-names></name>
<name><surname>Jackson</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol</article-title><source>Drug Metab. Dispos.</source><year>2021</year><volume>49</volume><fpage>882</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1124/dmd.120.000350</pub-id><pub-id pub-id-type="pmid">34330718</pub-id>
</element-citation></ref><ref id="B59-jox-15-00066"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biswas</surname><given-names>M.</given-names></name>
</person-group><article-title>Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients</article-title><source>Pharmacogenomics</source><year>2021</year><volume>22</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.2217/pgs-2020-0096</pub-id><pub-id pub-id-type="pmid">33759544</pub-id>
</element-citation></ref><ref id="B60-jox-15-00066"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wolking</surname><given-names>S.</given-names></name>
<name><surname>Schaeffeler</surname><given-names>E.</given-names></name>
<name><surname>Lerche</surname><given-names>H.</given-names></name>
<name><surname>Schwab</surname><given-names>M.</given-names></name>
<name><surname>Nies</surname><given-names>A.T.</given-names></name>
</person-group><article-title>Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature</article-title><source>Clin. Pharmacokinet.</source><year>2015</year><volume>54</volume><fpage>709</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0267-1</pub-id><pub-id pub-id-type="pmid">25860377</pub-id>
</element-citation></ref><ref id="B61-jox-15-00066"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>R.J.</given-names></name>
<name><surname>Lou</surname><given-names>T.T.</given-names></name>
<name><surname>Wu</surname><given-names>Y.F.</given-names></name>
<name><surname>Chen</surname><given-names>W.S.</given-names></name>
</person-group><article-title>Single nucleotide polymorphisms of ABCB1 gene and response to etanercept treatment in patients with ankylosing spondylitis in a Chinese Han population</article-title><source>Medicine</source><year>2017</year><volume>96</volume><fpage>e5929</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000005929</pub-id><pub-id pub-id-type="pmid">28151874</pub-id>
</element-citation></ref><ref id="B62-jox-15-00066"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benyamina</surname><given-names>A.</given-names></name>
<name><surname>Bonhomme-Faivre</surname><given-names>L.</given-names></name>
<name><surname>Picard</surname><given-names>V.</given-names></name>
<name><surname>Sabbagh</surname><given-names>A.</given-names></name>
<name><surname>Richard</surname><given-names>D.</given-names></name>
<name><surname>Blecha</surname><given-names>L.</given-names></name>
<name><surname>Rahioui</surname><given-names>H.</given-names></name>
<name><surname>Karila</surname><given-names>L.</given-names></name>
<name><surname>Lukasiewicz</surname><given-names>M.</given-names></name>
<name><surname>Farinotti</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2009</year><volume>33</volume><fpage>1270</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.07.016</pub-id><pub-id pub-id-type="pmid">19625010</pub-id>
</element-citation></ref><ref id="B63-jox-15-00066"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kebir</surname><given-names>O.</given-names></name>
<name><surname>Lafaye</surname><given-names>G.</given-names></name>
<name><surname>Blecha</surname><given-names>L.</given-names></name>
<name><surname>Chaumette</surname><given-names>B.</given-names></name>
<name><surname>Mouaffak</surname><given-names>F.</given-names></name>
<name><surname>Laqueille</surname><given-names>X.</given-names></name>
<name><surname>Benyamina</surname><given-names>A.</given-names></name>
</person-group><article-title>ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in heavy cannabis users</article-title><source>Psychiatry Res.</source><year>2017</year><volume>262</volume><fpage>357</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2017.09.006</pub-id><pub-id pub-id-type="pmid">28917442</pub-id>
</element-citation></ref><ref id="B64-jox-15-00066"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henquet</surname><given-names>C.</given-names></name>
<name><surname>Rosa</surname><given-names>A.</given-names></name>
<name><surname>Krabbendam</surname><given-names>L.</given-names></name>
<name><surname>Papiol</surname><given-names>S.</given-names></name>
<name><surname>Fananas</surname><given-names>L.</given-names></name>
<name><surname>Drukker</surname><given-names>M.</given-names></name>
<name><surname>Ramaekers</surname><given-names>J.G.</given-names></name>
<name><surname>van Os</surname><given-names>J.</given-names></name>
</person-group><article-title>An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>2748</fpage><lpage>2757</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301197</pub-id><pub-id pub-id-type="pmid">16936704</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="jox-15-00066-f001"><label>Figure 1</label><caption><p>Influence of the route of administration (oral and inhaled cannabis) on BDNF levels (Panel (<bold>A</bold>), pg/mL) (<italic toggle="yes">p</italic> = 0.004) and on interleukin-10 levels (panel (<bold>B</bold>), pg/mL) (<italic toggle="yes">p</italic> = 0.009). Outliers are represented by little circles, and extreme outliers are represented by little stars, the line in A represents BDNF levels in healthy subjects.</p></caption><graphic xlink:href="jox-15-00066-g001" position="float"/></fig><fig position="float" id="jox-15-00066-f002"><label>Figure 2</label><caption><p>Influence of <italic toggle="yes">COMT</italic> 680 T&#x0003e;C on &#x00394;9-THC plasma levels (ng/mL) (<italic toggle="yes">p</italic> = 0.017). TT N = 11; TC/CC N = 47. Extreme outliers are represented by little stars.</p></caption><graphic xlink:href="jox-15-00066-g002" position="float"/></fig><table-wrap position="float" id="jox-15-00066-t001"><object-id pub-id-type="pii">jox-15-00066-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of enrolled patients. Abbreviations: IQR = interquartile range (reproduced or adapted from [<xref rid="B35-jox-15-00066" ref-type="bibr">35</xref>], with permission from publisher Alessandra Manca, 2024).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">No. of patients</td><td align="center" valign="middle" rowspan="1" colspan="1">58</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cigarette smokers, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (32.8%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender (male), n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (34.5%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caucasian, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">20.6 (17.9; 23.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years), median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">61 (52; 67)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fibromyalgia, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (46.6%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Headache, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (8.6%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (6.9%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polytraumatized patients, n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38 (65.5%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jox-15-00066-t002"><object-id pub-id-type="pii">jox-15-00066-t002_Table 2</object-id><label>Table 2</label><caption><p><italic toggle="yes">Cannabis</italic> dosages (mg).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Cannabis</italic> mg</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Patients</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;250 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (43.0%)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">300&#x02013;500 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (39.7%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;500 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (17.3%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jox-15-00066-t003"><object-id pub-id-type="pii">jox-15-00066-t003_Table 3</object-id><label>Table 3</label><caption><p>Differences in median and IQR of plasma cannabinoid in patients treated with inhaled and oral (decoction) cannabis with high levels of THC. IQR = interquartile range (reproduced or adapted from [<xref rid="B35-jox-15-00066" ref-type="bibr">35</xref>], with permission from publisher Alessandra Manca, 2024).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Medical Cannabis with High Levels of THC</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhaled Cannabis, <break/>ng/mL Median (IQR)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral Cannabis (Decoction), ng/mL Median (IQR) </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x00394;9-THC</td><td align="center" valign="middle" rowspan="1" colspan="1">14.26 (5.70; 23.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.08 (4.53; 11.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11-OH-THC</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 11.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COOH-THC</td><td align="center" valign="middle" rowspan="1" colspan="1">62.99 (27.85; 248.33)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.53 (6.62; 23.59)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COOH-THC-glucuronide</td><td align="center" valign="middle" rowspan="1" colspan="1">511.35 (103.44; 1076.27)</td><td align="center" valign="middle" rowspan="1" colspan="1">47.92 (7.32; 80.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CBD</td><td align="center" valign="middle" rowspan="1" colspan="1">5.26 (1.45; 11.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.94 (0.56; 5.73)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.364</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7-OH-CBD</td><td align="center" valign="middle" rowspan="1" colspan="1">2.26 (0.79; 9.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">THCA</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 2.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.35 (0; 11.75)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.127</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0; 0.41)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0; 0.95)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.546</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jox-15-00066-t004"><object-id pub-id-type="pii">jox-15-00066-t004_Table 4</object-id><label>Table 4</label><caption><p>Differences in median and IQR of plasma cannabinoid in patients treated with inhaled and oral (decoction) cannabis with THC and CBD Level Standardized at Concentration of 6.5% and 8%. IQR = interquartile range(reproduced or adapted from [<xref rid="B35-jox-15-00066" ref-type="bibr">35</xref>], with permission from publisher Alessandra Manca, 2024.).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Medical Cannabis with THC and CBD Level Standardized at Concentration of 6.5% and 8%</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cannabinoids</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhaled Cannabis, <break/>ng/mL Median (IQR)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral Cannabis (Decoction), ng/mL Median (IQR) </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x00394;9-THC</td><td align="center" valign="middle" rowspan="1" colspan="1">5.85 (4.60; /)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.52 (4.18; 5.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.326</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11-OH-THC</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 1.39)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.412</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COOH-THC</td><td align="center" valign="middle" rowspan="1" colspan="1">43.76 (5.21; /)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.43 (4.91; 21.70)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.517</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COOH-THC-glucuronide</td><td align="center" valign="middle" rowspan="1" colspan="1">197.70 (17.81; /)</td><td align="center" valign="middle" rowspan="1" colspan="1">35.07 (10.35; 63.88)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.404</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CBD</td><td align="center" valign="middle" rowspan="1" colspan="1">7.83 (3.44; /)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.12 (0; 3.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.104</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7-OH-CBD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 (0; /)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 1.67)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.667</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">THCA</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.89 (0; 9.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0; 0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05 (0; 5.76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.118</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jox-15-00066-t005"><object-id pub-id-type="pii">jox-15-00066-t005_Table 5</object-id><label>Table 5</label><caption><p>Median biomarker levels in plasma for all the analyzed patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biomarkers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Median (Interquartile Range)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor alpha, (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">110.40 (98.43; 140.90)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Interleukin-6, (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">73.8 (68.1; 88.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Interleukin-10, (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">245.3 (222.7; 307.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Brain-derived neurotrophic factor, (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1672.6 (912.4; 5384.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurofilament Light Chain, (pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.96 (4.53; 9.72)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jox-15-00066-t006"><object-id pub-id-type="pii">jox-15-00066-t006_Table 6</object-id><label>Table 6</label><caption><p>Single-nucleotide polymorphisms influence cannabinoid levels (<italic toggle="yes">p</italic>-values are reported).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Cannabis Metabolites</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;9-THC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OH-THC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COOH-THC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COOH-THC-Glucuronide</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7-OH-CBD</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCA</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBDA</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CYP2D6</italic> 4180 CG/GG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CYP1A1</italic> 2794 AA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.045</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.020</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">COMT</italic> 680 TC/CC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.035</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">BSEP</italic> TC/CC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.037</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">BSEP</italic> CC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.047</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">ABCB1</italic> 1236 CT/TT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.040</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CYP1A2</italic> 890 CT/TT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.033</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: &#x00394;9-THC = &#x00394;9-tetrahydrocannabinol; CBD = cannabidiol; THCA = tetrahydrocannabinolic acid; CBDA = cannabidiolic acid.</p></fn></table-wrap-foot></table-wrap></floats-group></article>